Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0941820190290020133
Korean Journal of Clinical Pharmacy
2019 Volume.29 No. 2 p.133 ~ p.137
Visual Field Defect after Taking Atorvastatin/Ezetimibe, a Case Study
Kim Ji-Yoon

Lee Kyung-Gyu
Kim Jun-Young
Lee Jung-Min
Kim Na-Young
Lee Mo-Se
Ji Eun-Hee
Abstract
Atorvastatin is one of the most widely prescribed medications for dyslipidemia treatment. In Korea, post combined therapy with ezetimibe, a 73-year-old woman was reported by a community pharmacy to have experienced visual field defect, which recovered after drug discontinuation. She had never experienced this symptom before, and several studies have reported an association between use of statins and visual disorders such as blurred vision, diplopia, and cataract. Blockage of cholesterol accumulation, oxidative stress, or myopathy is expected to be a cause of this symptom. Naranjo scale, Korean causality assessment algorithm (Ver.2), and World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria were the three tools used to determine causality between the visual disorder and atorvastatin. The results represent ¡®probable¡¯, ¡®certain¡¯, and ¡®probable/likely¡¯ causality, respectively. Our results, in combination with a review of literature, indicate that ocular adverse effects are highly likely related to atorvastatin.
KEYWORD
Atorvastatin, visual field defect, adverse drug reaction, causality assessment
FullTexts / Linksout information
 
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI)